Real Word Evidence With 1L Polyethylene Glycol (PEG)+ Ascorbic Acid in Iberia

CompletedOBSERVATIONAL
Enrollment

13,393

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

March 1, 2022

Study Completion Date

March 1, 2022

Conditions
Colon CancerColon DiseaseColon Cleansing
Interventions
DRUG

1L PEG + ASCORBIC ACID

"* 2-Day Split-Dosing: The patient has taken the product in the evening before the scheduled colonoscopy and mandatory additional clear fluid. The patient has taken the second dose with mandatory additional clear fluids on the morning of the colonoscopy.~* Same Day: The patient has taken the first dose of the product on the day of the colonoscopy and take mandatory additional clear fluid. After a 1-2 hour break, the patient has taken a second dose plus additional clear mandatory fluid."

Trial Locations (12)

Unknown

Hospital da Senhora da Oliveira, Guimarães

Hospital CUF Descobertas, Lisbon

Consorci Corporació Sanitària Parc Taulí, Sabadell

Hospital San Rafael, A Coruña

HM Sant Jordi, Barcelona

Hospital del Mar, Barcelona

Hospital Doctor López Cano, Cadiz

Complejo hospitalario Ruber Juan Bravo, Madrid

Hospital Clinico San Carlos, Madrid

Hospital La Zarzuela, Madrid

Hospital Quirón salud Sagrado Corazón, Seville

Consorcio Hospitalario Provincial de Castelló, Valencia

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Xolomon Tree S.L.

UNKNOWN

lead

Norgine

INDUSTRY

NCT05174845 - Real Word Evidence With 1L Polyethylene Glycol (PEG)+ Ascorbic Acid in Iberia | Biotech Hunter | Biotech Hunter